32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The aim of the work is to evaluate the transdermal potential of novel vesicular carrier, ethosomes, bearing aceclofenac, Non-steroidal anti-inflammatory drugs having limited transdermal permeation. Aceclofenac loaded ethosomal carriers were prepared, optimized and characterized for vesicular shape and surface morphology, scanning electronic microscopy, vesicular size, entrapment efficiency, stability, in- vitro release study.The formulation having 3% phospholipids content and 40% ethanol showing the grater entrapment and optimal average vesicle size of formulation was determine by Malvern…mehr

Produktbeschreibung
The aim of the work is to evaluate the transdermal potential of novel vesicular carrier, ethosomes, bearing aceclofenac, Non-steroidal anti-inflammatory drugs having limited transdermal permeation. Aceclofenac loaded ethosomal carriers were prepared, optimized and characterized for vesicular shape and surface morphology, scanning electronic microscopy, vesicular size, entrapment efficiency, stability, in- vitro release study.The formulation having 3% phospholipids content and 40% ethanol showing the grater entrapment and optimal average vesicle size of formulation was determine by Malvern Zetamaster & found 0.696 m and zeta potential of formulation was -6.74 mV. The vesicular suspension was kept in sealed vials (10ml) at 4 ± 2ºC and at room temperature for 45 days no change is shown in the entrapment efficiency. The optimized ethosomal formulation showed transdermal flux (226.1 g/cm²/hr) for ethanolic drug solution which is grater then that of isopropyl alcohol solution (159.0 g/cm²/hr). The result advocates the potential of ethosome formulation to treat rheumatic disease where facilitated penetration of the drug into muscle and synovial fluid is desirable.